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Abstract
Background: Mitochondrial aldehyde dehydrogenase (ALDH2) displays some promise in the protection against
cardiovascular diseases although its role in diabetes has not been elucidated.
Methods: This study was designed to evaluate the impact of ALDH2 on streptozotocin-induced diabetic
cardiomyopathy. Friendly virus B(FVB) and ALDH2 transgenic mice were treated with streptozotocin (intraperitoneal
injection of 200 mg/kg) to induce diabetes.
Results: Echocardiographic evaluation revealed reduced fractional shortening, increased end-systolic and -diastolic
diameter, and decreased wall thickness in streptozotocin-treated FVB mice. Streptozotocin led to a reduced respiratory
exchange ratio; myocardial apoptosis and mitochondrial damage; cardiomyocyte contractile and intracellular Ca2+
defects, including depressed peak shortening and maximal velocity of shortening and relengthening; prolonged
duration of shortening and relengthening; and dampened intracellular Ca2+ rise and clearance. Western blot analysis
revealed disrupted phosphorylation of Akt, glycogen synthase kinase-3b and Foxo3a (but not mammalian target of
rapamycin), elevated PTEN phosphorylation and downregulated expression of mitochondrial proteins, peroxisome
proliferator-activated receptor g coactivator 1a and UCP-2. Intriguingly, ALDH2 attenuated or ablated streptozotocin-
induced echocardiographic, mitochondrial, apoptotic and myocardial contractile and intracellular Ca2+ anomalies as
well as changes in the phosphorylation of Akt, glycogen synthase kinase-3b, Foxo3a and phosphatase and tensin
homologue on chromosome ten, despite persistent hyperglycemia and a low respiratory exchange ratio. In vitro data
revealed that the ALDH2 activator Alda-1 and glycogen synthase kinase-3b inhibition protected against high glucose-
induced mitochondrial and mechanical anomalies, the effect of which was cancelled by mitochondrial uncoupling.
Conclusions: In summary, our data revealed that ALDH2 acted against diabetes-induced cardiac contractile and
intracellular Ca2+ dysregulation, possibly through regulation of apoptosis, glycogen synthase kinase-3b activation
and mitochondrial function independent of the global metabolic profile.
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Background
The mitochondrial isoform of aldehyde dehydrogenase
(ALDH2) has been shown to play a pivotal role in the
metabolism of acetaldehyde and other toxic aldehydes
[1-4]. Ample evidence from our laboratory as well as
others has revealed a rather singular role for ALDH2 in
cardioprotection against ischemic injury, arrhythmias
and alcoholism [2,3,5-7]. However, the role of ALDH2
in myopathic anomalies associated with metabolic disor-
ders, including diabetes mellitus, has not been eluci-
dated. The prevalence of diabetes and associated heart
diseases has been steadily increasing, particularly in
Asian countries, with approximately 50% of populations
carrying one copy of the mutant ALDH2 gene [4,8-11].
* Correspondence: jren@uwyo.edu
1Department of Cardiology, Xijing Hospital, Fourth Military Medical
University, Xi’an, 710032, China
Full list of author information is available at the end of the article
Zhang et al. BMC Medicine 2012, 10:40
http://www.biomedcentral.com/1741-7015/10/40
© 2012 Zhang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
A plethora of studies have depicted significant contribu-
tion from genetic variants, such as peroxisome prolifera-
tor-activated receptors (PPARs), in the predisposition of
diabetes [12]; however, very few have examined the role
of ALDH2 in the onset and progression of diabetes and
its complications. Recent evidence revealed that ALDH2
polymorphism is closely associated with an increased
risk of diabetes [11] while experimental findings showed
reduced ALDH2 expression and activity associated with
oxidative stress and cardiac dysfunction in diabetes [13].
These observations are somewhat consistent with the
notion that inactive ALDH2 promotes hyperglycemia
[9], while genotypes of ALDH2 can modify diabetes risk
irrespective of alcohol intake [14]. To this end, this
study was designed using a unique murine model to
examine the impact of ALDH2 overexpression in the
pathogenesis of diabetic cardiomyopathy and the under-
lying cellular mechanism(s) involved. Recent evidence
from our group has revealed a pivotal role for the essen-
tial survival factor Akt and its downstream signaling
molecules, including glycogen synthase kinase-3b
(GSK3b), PPAR (mTOR) and the forkhead transcrip-
tional factor in ALDH2, in cardioprotection against
alcoholism and ischemia-reperfusion [3,7,15]. To better
elucidate the interplay between these signaling cascades
and mitochondrial function in diabetes and/or ALDH2-
induced cardiac responses, we scrutinized apoptosis and
mitochondrial integrity, including mitochondrial mem-
brane potential, as well as cell signaling of Akt, GSK3b,
mTOR and Foxo3a in wild-type FVB and ALDH2 trans-
genic mice with or without the induction of experimen-
tal diabetes. Given that Akt signaling is under the
negative control of phosphatase and tensin homologue
on chromosome ten (PTEN) in a wide variety of disease
conditions, including myocardial hypertrophy, heart fail-
ure and preconditioning [16], we monitored pan protein
expression and phosphorylation of PTEN. To evaluate if
ALDH2 affects myocardial morphometric and functional
anomalies in diabetes through any potential effect sec-
ondary to global metabolic alterations, we scrutinized
whole body metabolism, including the respiratory
exchange ratio (RER), and total physical activity as well
as plasma levels of free fatty acid, insulin and glucose
(fasting and postprandial) in control and diabetic mice.
Methods
Experimental animals, experimental diabetes and ALDH2
activity
All animal procedures were approved by our Institutional
Animal Care and Use Committee at the University of
Wyoming (Laramie, WY, USA). Production of ALDH2
transgenic mice using the chicken b-actin promoter was
as described previously [5]. All mice were housed in a
temperature-controlled room under a 12 hour light-12
hour dark circadian cycle with access to water and food
ad libitum. Five-month-old male FVB (used as wild-type)
and ALDH2 transgenic mice received intraperitoneal
injections of streptozotocin (STZ, 200 mg/kg). All mice
were maintained for four weeks with free access to stan-
dard laboratory chow and tap water before their blood
glucose levels were monitored. Mice with fasting blood
glucose levels > 13 mM were deemed diabetic [17].
ALDH2 activity was measured in 33 mM sodium pyro-
phosphate containing 0.8 mM NAD+, 15 μM propionalde-
hyde and 0.1 mL protein extract. Propionaldehyde, the
substrate of ALDH2, was oxidized in propionic acid, while
NAD+ was reduced to NADH to estimate ALDH2 activity.
NADH was determined by spectrophotometric absorbance
at 340 nm. ALDH2 activity was expressed as nanomoles
NADH per minute per milligram of protein [18].
Serum free fatty acid, plasma insulin and blood glucose
levels
Plasma free fatty acids were measured three hours after
mice were denied access to food using a Free Fatty Acid
Assay Kit (Cayman Chemical, MI, USA). In brief, mouse
blood samples were centrifuged at 2000 × g for 15 minutes
at 4°C. An excitation wavelength of 530 nm and an emis-
sion wavelength of 590 nm were used to detect the quan-
tity of free fatty acids. Plasma insulin levels were measured
using a mouse insulin ELISA kit from Diagnostic System
Laboratory (Webster, TX, USA). Fasting (overnight) and
postprandial (two hours after re-feeding following the
overnight fasting) blood glucose levels were determined
using a glucometer (Accu-ChekII, model 792, Boehringer
Mannheim Diagnostics, Indianapolis, IN, USA) [17].
Metabolic measurement
Indirect calorimetry and total physical activity were
measured in light (10 a.m.) and dark (10 p.m.) phases
using the Comprehensive Laboratory Animal Monitor-
ing System (Oxymax/CLAMS; Columbus Instruments,
Columbus, OH, USA). Volume of oxygen intake (VO2),
volume of Carbon Dioxide exhaled (VCO2), the RER
(VCO2/VO2) and physical activity were measured. All
the parameters were measured every 10 minutes for six
hours during daytime and six hours during nighttime.
Result recorded in the first and last half hour was not
be used. For simplicity, only the RER is presented with-
out displaying original data from VO2 and VCO2 [19].
Echocardiographic assessment
Cardiac geometry and function were evaluated in
anesthetized mice using a two-dimensional guided M-
mode echocardiography (Sonos 5500; Phillips Medical
System, Andover, MA, USA) equipped with a 15-6 MHz
linear transducer. Left ventricular (LV) wall thickness
and diastolic and systolic dimensions were recorded
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from the M-mode images. Fractional shortening was cal-
culated from end-diastolic diameter (EDD) and end-sys-
tolic diameter (ESD) using the equation:
(EDD− ESD)/EDD× 0.01
Estimated echocardiographic LV mass was calculated
as:
[(LVEDD + septal wall thickness + posterior wall thickness)3− LVEDD3]× 1.055
where 1.055 (in mg/mm3) represents the density of
the myocardium. Heart rate was calculated from 20 con-
secutive cardiac cycles [20].
Isolation of murine cardiomyocytes
After intraperitoneal administration of a sedative (keta-
mine 80 mg/kg and xylazine 12 mg/kg), the hearts were
removed and digested for 20 minutes with Liberase
Blendzyme 4 (Hoffmann-La Roche Inc., Indianapolis,
IN, USA). Cardiomyocyte yield was approximately 75%
and was not affected by STZ treatment or ALDH2 over-
expression. Only rod-shaped myocytes with clear edges
were selected for the mechanical study [21].
For the in vitro study, cardiomyocytes from control
FVB mice were exposed to high extracellular glucose
(25.5 mM) [22] in the absence or presence of the ALDH2
activator Alda-1 (20 μM), the mitochondrial uncoupler
carbonyl cyanide 4-trifluoromethoxyphenylhydrazone
(FCCP, 1 μM) or the GSK3b inhibitor SB216763 (10 μM)
[23,24] for 12 hours before an assessment of their
mechanical and biochemical properties.
Cell shortening and relengthening
The mechanical properties of cardiomyocytes were
assessed using a SoftEdge MyoCam system (IonOptix Cor-
poration, Milton, MA, USA) [5]. In brief, cells were placed
in a Warner chamber mounted on the stage of an inverted
microscope (Olympus, IX-70, Olympus Corporation,
Tokyo, Japan) and superfused (approximately 1 mL/min at
25°C) with a buffer containing 131 mM NaCl, 4 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 10 mM glucose and 10 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), at pH 7.4. The cells were field-stimulated with a
supra-threshold voltage at a frequency of 0.5 Hz for 3 ms
using a pair of platinum wires placed on opposite sides of
the chamber connected to a FHC stimulator (Brunswick,
NE, USA). The studied myocyte was displayed on the
computer monitor using an IonOptix MyoCam camera.
IonOptix SoftEdge software was used to capture changes
in cell length. Cell shortening and relengthening were
assessed using the following indices: peak shortening (PS),
the peak ventricular contractility; time-to-PS (TPS; con-
traction duration) and time-to-90% relengthening (TR90),
the cardiomyocyte relaxation duration; and maximal
velocities of shortening (+dL/dt) and relengthening (-dL/
dt), the maximal velocities of ventricular pressure rise and
fall.
Intracellular Ca2+ transient measurement
Myocytes were loaded with fura-2-acetoxymethyl ester
(0.5 μM) for 10 minutes and fluorescence measurements
were recorded with a dual-excitation fluorescence photo-
multiplier system (IonOptix). Cardiomyocytes were
placed on an Olympus IX-70 inverted microscope and
imaged through a Fluor × 40 oil objective. Cells were
exposed to light emitted by a 75 W lamp and passed
through either a 360 or a 380 nm filter, while being sti-
mulated to contract at 0.5 Hz. Fluorescence emissions
were detected between 480 and 520 nm by a photomulti-
plier tube after first illuminating the cells at 360 nm for
0.5 seconds then at 380 nm for the duration of the
recording protocol (333 Hz sampling rate). The 360 nm
excitation scan was repeated at the end of the protocol
and qualitative changes in intracellular Ca2+ concentra-
tion were inferred from the ratio of fura-2 fluorescence
intensity (FFI) at the two wavelengths (360 and 380 nm).
Fluorescence decay time was measured as an indication
of the intracellular Ca2+ clearing rate. Both single- and
bi-exponential curve fit programs were applied to calcu-
late the intracellular Ca2+ decay constant [5].
Histological examination
After anesthesia, hearts were excised and immediately
placed in 10% neutral-buffered formalin at room tem-
perature for 24 hours after a brief rinse with PBS. The
specimens were embedded in paraffin, cut into 5 μm
sections and stained with H & E as well as fluorescein
isothiocyanate (FITC)-conjugated wheat germ agglutinin.
Heart sections were stained with H & E for gross mor-
phology analysis. Thereafter, the slides were washed
three times with PBS, mounted with aqueous mounting
media and cover-slipped. Cardiomyocyte cross-sectional
areas were calculated on a digital microscope (× 400)
using the Image J (version1.34S) software [5,20].
Caspase-3 assay
Tissue homogenates were centrifuged (10,000 g at 4°C, 10
minutes) and pellets were lysed in an ice-cold cell lysis
buffer. The assay was carried out in a 96-well plate with
each well containing 30 μL cell lysate, 70 μL of assay buf-
fer (50 mM HEPES, 0.1% 3-([3-cholamidopropyl]-
dimethyllammonio)-1-propanesulfonate (CHAPS), 100
mM NaCl, 10 mM dithiothreitol and 1 mM ethylenedia-
minetetraacetic acid) and 20 μL of caspase-3 colorimetric
substrate Ac-DEVD-pNA. The 96-well plate was incu-
bated at 37°C for one hour, during which time the caspase
in the sample was allowed to cleave the chromophore
pNA from the substrate molecule. Caspase-3 activity was
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expressed as picomoles of pNA released per microgram of
protein per minute [5].
Aconitase activity
Mitochondrial aconitase, an iron-sulfur enzyme located
in the citric acid cycle, is readily damaged by oxidative
stress via removal of an iron from the [4Fe-4S] cluster.
Mitochondrial fractions prepared from whole heart
homogenate were resuspended in 0.2 mM sodium citrate.
An aconitase activity assay (Aconitase Activity Assay Kit,
Aconitase-340 Assay; OxisResearch, Portland, OR, USA)
was performed according to the manufacturer instruc-
tions with minor modifications. Briefly, the mitochon-
drial sample (50 μL) was mixed in a 96-well plate with 50
μL trisodium citrate (substrate) in Tris-HCl pH 7.4, 50
μL isocitrate dehydrogenase (enzyme) in Tris-HCl, and
50 μL NADP in Tris-HCl. After incubating for 15 min-
utes at 37°C, the absorbance was dynamically recorded at
340 nm every minute for five minutes with a spectro-
photometer. During the assay, citrate is isomerized by
aconitase into isocitrate and eventually a-ketoglutarate.
The Aconitase-340 Assay measures NADPH formation, a
product of the oxidation of isocitrate to a-ketoglutarate.
Tris-HCl buffer (pH 7.4) was served as the blank [25].
Terminal deoxynucleotidyl transferase mediated dUTP
nick end labeling assay
Terminal deoxynucleotidyl transferase mediated dUTP
nick end labeling (TUNEL) staining of myonuclei positive
for DNA strand breaks was determined using a fluores-
cence detection kit (Roche, Indianapolis, IN, USA) and
fluorescence microscopy. Paraffin-embedded sections (5
μm) were incubated with Proteinase K solution for 30
minutes. TUNEL reaction mixture containing terminal
deoxynucleotidyl transferase and fluorescein-dUTP was
added to the sections in 50 μL drops and incubated for
60 minutes at 37°C in a humidified chamber in the dark.
The sections were rinsed three times in PBS for five min-
utes each. Following embedding, sections were visualized
with an Olympus BX-51 microscope equipped with an
Olympus MaguaFire SP digital camera. DNase I and label
solution were used as positive and negative controls. To
determine the percentage of apoptotic cells, micrographs
of TUNEL-positive and 4’-6-dia!midino-2-phenylindole-
stained nuclei were captured using an Olympus fluores-
cence microscope and counted using the ImageJ software
(ImageJ version 1.43r; National Institutes of Health) fol-
lowed by manual exclusion of the false-positive staining
from 10 random fields at 400 × magnification. At least
100 cells were counted in each field [26].
Measurement of mitochondrial membrane potential
Murine cardiomyocytes were suspended in HEPES saline
buffer and the mitochondrial membrane potential (ΔΨm)
was detected as previously described [27]. Briefly, after
incubation with JC-1 (5 μM) for 10 minutes at 37°C, cells
were rinsed twice by sedimentation using the HEPES sal-
ine buffer free of JC-1 before being examined under a
confocal laser scanning microscope (Leica TCS SP2,
Leica Microsystems Inc. Buffalo Grove, IL, USA) at an
excitation wavelength of 490 nm. The emission of fluor-
escence was recorded at 530 nm (monomer form of JC-1,
green) and at 590 nm (aggregate form of JC-1, red).
Results in fluorescence intensity were expressed as the
590 nm to 530 nm emission ratio. The mitochondrial
uncoupler carbonyl cyanide m-chlorophenylhydrazone
(10 μM) was used as a positive control for the mitochon-
drial membrane potential measurement.
Western blot analysis
The myocardial protein was prepared as previously
described [27]. The antibodies used for western blotting
included anti-PGC-1a, anti-UCP-2 (EMD Millipore Bill-
erica, MA, USA), anti-ALDH2 (gift from Dr. Henry
Weiner, Purdue University, West Lafayette, IN, USA),
anti-GSK3b, anti-phosphorylated(p)-GSK3b (Ser9), anti-
Akt, anti-pAkt (Thr308), anti-Foxo3a, anti-pFoxo3a
(Thr32), anti-mTOR, anti-pmTOR (Ser2448), anti-PTEN,
anti-pPTEN (Ser380), anti-sarcoendoplasmic reticulum
Ca2+-ATPase (SERCA2a; Affinity Bioreagents Inc.,
Golden, CO, USA), anti-Na+-Ca2+ exchanger (1:1000;
Sigma, St. Louis, MO, USA), anti-phospholamban
(1:500; Abcam, Cambridge, MA, USA) and anti-glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH; loading
control). Antibodies for GSK3b, pGSK3b, Akt, pAkt,
Foxo3a, pFoxo3a, mTOR, pmTOR, PTEN and pPTEN
were purchased from Cell Signaling Technology (Bev-
erly, MA, USA) while antibody for PGC-1a was
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) unless otherwise indicated. The membranes
were incubated with horseradish peroxidase-coupled
secondary antibodies. After immunoblotting, films were
scanned and detected with a Bio-Rad Calibrated Densit-
ometer Hercules, CA, USA)
Data analysis
Data are presented as the mean ± standard error of the
mean (SEM). Statistical comparison was performed by a
one-way analysis of variance (ANOVA), with a two-way
ANOVA for RER and physical activity studies, followed
by Tukey’s post hoc test. Significance was set as P <
0.05.
Results
General features, mitochondrial and metabolic properties
of normal and diabetic mice
STZ treatment significantly reduced body but not organ
weights in FVB and ALDH2 mice. Although STZ
Zhang et al. BMC Medicine 2012, 10:40
http://www.biomedcentral.com/1741-7015/10/40
Page 4 of 17
treatment did not affect the size of the kidney (organ-to-
body weight ratio), it overtly increased heart and liver
sizes in FVB but not ALDH2 mice. ALDH2 transgene
did not affect the body and organ weights or organ
sizes. As expected, blood glucose (fasting and postpran-
dial) and free fatty acid levels were significantly elevated
whereas plasma insulin levels were severely decreased in
STZ-challenged mice compared with the non-diabetic
FVB mice. ALDH2 did not affect the levels of fasting or
postprandial blood glucose, serum free fatty acids or
plasma insulin in either normal or diabetic groups
(Table 1). Furthermore, experimental diabetes decreased
both protein level and enzymatic activity of ALDH2, the
effect of which was masked by ALDH2 overexpression.
STZ elicited overt apoptosis (as evidenced by caspase-3
activity) and mitochondrial damage (reduced aconitase
activity). Although ALDH2 enzymatic overexpression
itself had little effect on apoptosis and mitochondrial
function, it significantly attenuated or nullified diabetes-
induced apoptosis and mitochondrial damage (Figure 1).
To evaluate the impact of ALDH2 overexpression on
metabolic indices, calorimetric parameters were obtained
in control and diabetic FVB and ALDH2 mice using the
six-chamber Oxymax system (Columbus Instruments,
Columbus, OH, USA) as previously described [19]. Dia-
betic FVB and ALDH2 mice had a significantly lower
RER (VCO2/VO2), especially during the dark cycle, com-
pared with control FVB and ALDH2 mice. This diabetes-
associated change in RER was not due to altered physical
activity. There was little difference in physical activity
among the four mouse groups tested (Figure 2). These
results indicate that STZ-induced diabetic mice oxidized
a lower proportion of carbohydrate compared with con-
trol mice, reflecting a higher fractional reliance on lipid
rather than glucose as the main energy source. ALDH2
overexpression did not alter the energy source globally in
control or diabetic mice.
Echocardiographic properties of normal and diabetic
mice
Heart rate and absolute LV mass (calculated using echo-
cardiography) were comparable among all mouse
groups, regardless of diabetic or ALDH2 state. However,
diabetes increased the normalized LV mass value in the
FVB but not ALDH2 group, consistent with its effect on
gross heart weights. Experimental diabetes significantly
increased EDD and ESD and decreased wall thickness,
the effect of which was mitigated by ALDH2. Interest-
ingly, STZ treatment significantly depressed fractional
shortening in FVB mice. ALDH2 mitigated the diabetes-
induced decrease in fractional shortening without elicit-
ing any effect itself (Figure 3).
Cardiomyocyte contractile and intracellular Ca2+
properties
Neither experimental diabetes nor ALDH2 overexpression
affected resting cell length, as depicted in Figure 4. Experi-
mental diabetes significantly reduced PS and maximal
velocity of shortening and relengthening (± dL/dt) as well
as prolonged TPS and TR90 in FVB cardiomyocytes, remi-
niscent of our earlier findings [28,29]. Importantly,
ALDH2 abolished diabetes-induced mechanical abnormal-
ities without eliciting any notable effect by itself. To
explore the potential mechanism of action involved in the
ALDH2-elicited beneficial effects against experimental dia-
betes, fura-2 fluorescence microscopy was employed to
monitor the intracellular Ca2+ homeostasis. Data pre-
sented in Figure 5 reveal a significantly depressed intracel-
lular Ca2+ rise in response to electrical stimulus (ΔFFI)
and reduced intracellular Ca2+ decay rate (single or bi-
exponential curve fit) along with unchanged baseline intra-
cellular Ca2+ in cardiomyocytes from STZ-treated mouse
hearts. ALDH2 overexpression negated STZ-induced pro-
longation in intracellular Ca2+ decay and depression in
ΔFFI with little effect on baseline FFI. Last but not least,
Table 1 Biometric parameters of control or diabetic FVB and ALDH2 mice
Parameter FVB FVB-STZ ALDH2 ALDH2-STZ
Body weight (g) 30.3 ± 1.3 24.2 ± 0.7a 29.5 ± 1.1 26.1 ± 0.8a
Heart weight (mg) 165 ± 9 171 ± 8 163 ± 6 159 ± 5
Heart/body weight ratio (mg/g) 5.45 ± 0.19 7.23 ± 0.43a 5.66 ± 0.26 6.16 ± 0.18b
Liver weight (g) 1.54 ± 0.07 1.44 ± 0.07 1.52 ± 0.05 1.46 ± 0.06
Liver/body weight (mg/g) 51.2 ± 1.4 59.4 ± 2.3a 51.9 ± 1.9 54.9 ± 1.9
Kidney weight (g) 0.45 ± 0.03 0.39 ± 0.02 0.42 ± 0.02 0.40 ± 0.03
Kidney/body weight (mg/g) 14.8 ± 0.4 16.1 ± 0.8 14.4 ± 0.4 15.4 ± 0.8
Plasma insulin (ng/mL) 0.27 ± 0.03 0.05 ± 0.01a 0.28 ± 0.03 0.06 ± 0.02a
Fasting blood glucose (mM) 5.50 ± 0.26 19.7 ± 1.5a 5.43 ± 0.18 18.5 ± 1.7a
Postprandial blood glucose (mM) 9.94 ± 0.67 25.3 ± 1.5a 10.57 ± 0.54 26.5 ± 1.8a
Plasma free fatty acids (mM) 1.00 ± 0.11 1.30 ± 0.04a 1.00 ± 0.15 1.25 ± 0.08a
Mean ± SEM, n = 21 to 22 mice per group. aP < 0.05 versus FVB group; bP < 0.05 versus FVB-STZ group.
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Figure 1 Influence of streptozotocin and ALDH2 on expression and activity of ALDH2, apoptosis and mitochondrial function. (A)
ALDH2 expression; (B) ALDH2 enzymatic activity measured using spectrophotometry; (C) caspase-3 activity; (D) mitochondrial aconitase activity.
Inset: Representative gel blots of ALDH2 and GAPDH (loading control) using specific antibodies. Mean ± SEM, n = 5 to 7 per group. *P < 0.05
versus FVB group; #P <0.05 versus FVB-STZ group.
Figure 2 Oxygen consumption and total activity during day and night time in FVB and ALDH2 transgenic mice treated with or
without streptozotocin. (A) Respiratory exchange ratio (RER) during day time; (B) RER at night; (C) total activity during day time; (D) total
activity at night. Mean ± SEM, n = 4 to 5 mice per group. *P < 0.05 versus FVB group for both STZ groups.
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the ALDH2 transgene itself did not affect the intracellular
Ca2+ indices tested.
Effect of ALDH2 on diabetes-induced change in
myocardial histology
To assess the impact of ALDH2 overexpression on myo-
cardial histology after STZ treatment, heart gross mor-
phology and the cardiomyocyte cross-sectional area were
examined. Low magnification transverse heart sections
indicated reduced LV wall thickness and enlarged cham-
ber size in mice with experimental diabetes, with lesser
alteration in ALDH2 transgenic mice. Findings from
FITC-conjugated wheat germ staining sections revealed
increased cardiomyocyte area after the induction of
experimental diabetes, consistent with increased normal-
ized LV mass, EDD and ESD in FVB-STZ mice. The
Figure 3 Echocardiographic properties in FVB and ALDH2 transgenic mice treated with or without streptozotocin. (A) Representative
echocardiographic images; (B) heart rate; (C) wall thickness; (D) left ventricular (LV) end-diastolic diameter; (E) LV end-systolic diameter; (F) LV
mass; (G) LV mass normalized to body weight; (H) fractional shortening. Mean ± SEM, n = 12 to 13 mice per group. *P <0.05 versus FVB group;
#P <0.05 versus FVB-STZ group.
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experimental diabetes-induced change in cardiomyocyte
size was effectively ablated by ALDH2 overexpression
while the ALDH2 transgene itself did not affect cardio-
myocyte size (Figure 6).
Effects of ALDH2 on diabetes-induced apoptosis and
mitochondrial damage
To further examine the mechanism(s) of action behind
ALDH2-elicited protection against STZ-induced cardiac
mechanical dysfunction, the myocardium and cardio-
myocytes from normal or diabetic FVB and ALDH2
mice were examined for myocardial apoptosis, using
TUNEL staining, and mitochondrial integrity, using JC-1
fluorescence microscopy. Results shown in Figure 7
(panels A-I) indicate that the TUNEL-positive cells were
more abundant in STZ-treated FVB mice, the effect of
which was significantly attenuated by ALDH2 overex-
pression. ALDH2 itself did not affect myocardial apop-
tosis. Our fluorescence data displayed in Figure 7
(panels J and K) revealed loss of mitochondrial mem-
brane potential in cardiomyocytes from STZ-treated
FVB mice, the effect of which was reconciled by ALDH2
overexpression. ALDH2 itself did not affect the mito-
chondrial membrane potential. These findings indicate a
Figure 4 Cardiomyocyte contractile properties in FVB and ALDH2 transgenic mice treated with or without streptozotocin. (A) Resting
cell length; (B) peak shortening (PS), normalized to cell length; (C) maximal velocity of shortening (+ dL/dt); (D) maximal velocity of
relengthening (- dL/dt); (E) time-to PS (TPS); (F) time-to-90% relengthening (TR90). Mean ± SEM, n = 101 to 102 cells from four mice per group.
*P <0.05 versus FVB group; #P <0.05 versus FVB-STZ group.
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corroborative role of apoptosis and mitochondrial func-
tion in ALDH2-offered cardioprotection against experi-
mental diabetes.
Expression of UCP-2, PGC1a, SERCA2a, Na+-Ca2+
exchanger and phospholamban
To explore the possible mechanism behind ALDH2 and
diabetes-induced responses on cardiac function, particu-
larly on mitochondrial function and intracellular Ca2+
homeostasis, western blot analysis was performed to
assess the levels of the key mitochondrial proteins UCP-2
and PGC1a as well as the essential intracellular Ca2+ reg-
ulatory proteins SERCA2a, Na+-Ca2+ exchanger and
phospholamban. Our data shown in Figure 8 depict that
diabetes significantly downregulated the expression of
UCP-2, PGC1a, SERCA2a and Na+-Ca2+ exchanger
while upregulating the level of phospholamban in FVB
mice. Although the ALDH2 transgene itself did not alter
the expression of UCP-2, PGC1a, SERCA2a, Na+-Ca2+
exchanger or phospholamban, it nullified STZ-induced
changes in all five.
Western blot analysis for Akt, GSK3b, Foxo3a, mTOR and
PTEN signaling
To examine possible signaling mechanism(s) involved in
the ALDH2-offered protection against diabetes-induced
myocardial anomalies, the expression and phosphoryla-
tion of post-insulin receptor signaling, including Akt
and the Akt downstream signaling molecules GSK3b,
Foxo3a and mTOR, were evaluated. Western blot find-
ings revealed that diabetes overtly dampened phosphory-
lation of Akt, GSK3b and Foxo3a without affecting that
of mTOR, the effect of which was mitigated by ALDH2
overexpression. Neither diabetes nor ALDH2 affected
the pan protein expression of Akt, Foxo3a or mTOR
(Figure 9). To explore the possible mechanisms respon-
sible for ALDH2- and experimental diabetes-elicited
changes in Akt phosphorylation, levels of pan and
pPTEN, a negative regulator of Akt signaling, were
examined in control and diabetic FVB and ALDH2
mice. Our data shown in Figure 10 revealed that STZ
treatment significantly increased phosphorylation of
PTEN (both absolute and normalized value) without
Figure 5 Cardiomyocyte intracellular Ca2+ handling properties in FVB and ALDH2 transgenic mice treated with or without
streptozotocin. (A) Resting fura-2 fluorescence intensity (FFI); (B) electrically-stimulated rise in FFI (ΔFFI); (C) intracellular Ca2+ decay rate (single
exponential); (D) intracellular Ca2+ decay rate (bi-exponential). Mean ± SEM, n = 76 to 77 cells from four mice per group. *P <0.05 versus FVB
group; #P <0.05 versus FVB-STZ group.
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affecting pan protein expression of PTEN, the effect of
which was mitigated by ALDH2 overexpression. The
ALDH2 transgene itself did not affect pan or phos-
phorylated levels of PTEN.
Influence of ALDH2 activation, mitochondrial uncoupling
and GSK3b inhibition on high glucose-induced
cardiomyocyte mitochondrial and contractile responses
To further examine the causal relationships between
ALDH2-induced mechanical and mitochondrial responses
in diabetes, cardiomyocytes from control FVB mice were
exposed to high glucose (25.5 mM) in the absence or pre-
sence of the ALDH2 activator Alda-1 (20 μM), the mito-
chondrial uncoupler FCCP (1 μM) or the GSK3b inhibitor
SB216763 (10 μM) for 12 hours [6,9,30] prior to an assess-
ment of mechanical and biochemical properties. Figure 11
depicts that high glucose significantly dampened mito-
chondrial function (shown as loss of aconitase activity)
and cardiomyocyte contractile function (shown as reduced
PS, ± dL/dt and prolonged TR90), the effect of which was
Figure 6 Histological analyses in hearts from FVB and ALDH2 transgenic mice treated with or without streptozotocin. (A-D) Representative
photomicrographs from gross morphological view of transverse myocardial sections (scale bar = 1 mm). (E-H) Representative fluorescein
isothiocyanate-conjugated wheat germ agglutinin staining depicting cardiomyocyte size (× 200; scale bar = 100 μm). (I) Quantitative cardiomyocyte
cross-sectional (transverse) area from 60 cells from three mice per group. Mean ± SEM, *P < 0.05 versus FVB; #P < 0.05 versus FVB-STZ group.
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abolished by Alda-1 and SB216763, without any additive
effect between the two. Interestingly, FCCP abolished
Alda-1-induced beneficial mitochondrial and mechanical
effects. There was little effect on mitochondrial integrity
and mechanical function by the pharmacological inhibitors
themselves (data not shown for FCCP).
Discussion
Earlier findings from our group indicated that ALDH2
may rescue against ischemic and alcoholic injuries to the
heart [3,7,15]. Data from this study provides, for the first
time, compelling evidence that ALDH2 protects against
diabetes-induced myocardial remodeling and contractile
defect through lessened apoptosis, preserved mitochon-
drial function and post-insulin receptor signaling,
including phosphorylation of Akt, GSK3b and Foxo3a
transcriptional factor. These data favor a likely role of the
activation of Akt and GSK3b as well as inactivation
(phosphorylation) of Foxo3a in ALDH2-elicited preserva-
tion of mitochondrial and mechanical function in dia-
betes. Our data further reveal that ALDH2 may preserve
Akt activation in diabetes through ablation of diabetes-
induced mitochondrial injury and/or increasing the phos-
phorylation of PTEN, a negative regulator of Akt [16]. An
analysis of global metabolism indicated that ALDH2
failed to alter diabetes-induced changes in plasma levels
of glucose (fasting and postprandial), insulin and serum
free fatty acids, the RER or total physical activity, exclud-
ing the possibility of a potential cardiac protective effect
secondary to any ALDH2-elicited global metabolic
Figure 7 Effect of streptozotocin and ALDH2 on myocardial apoptosis and mitochondrial membrane potential using TUNEL staining
and JC-1 fluorescence. TUNEL-positive nuclei were visualized with fluorescein (green) in panels (A) FVB, (C) FVB-STZ, (E) ALDH2 and (G)
ALDH2-STZ. All nuclei were stained with 4’-6-diamidino-2-phenylindole (blue) in panels (B) FVB, (D) FVB-STZ, (F) ALDH2 and (H) ALDH2-STZ.
Original magnification × 400. (I) Quantified data. (J) Quantitative analysis of cardiomyocyte mitochondrial membrane potential using JC-1 ratio in
FVB and ALDH2 mice treated with or without STZ (10 μM carbonyl cyanide m-chlorophenylhydrazone was used as a positive control). (K)
Representative JC-1 fluorochrome images depicting mitochondrial membrane potential in cardiomyocytes. Mean ± SEM, n = 12 and 7 fields
from three mice per group for panel I and J, respectively. *P < 0.05 versus FVB group; #P < 0.05 versus FVB-STZ group.
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benefits. Taken together, these findings should lead to a
better understanding of the role of ALDH2 in myocardial
anomalies in diabetes.
Reduced contractility and prolonged duration of systole
as well as diastole are hallmarks of diabetic cardiomyopa-
thy [17,28,29]. Findings from our present study revealed
reduced fractional shortening; enlarged EDD and ESD;
decreased wall thickness, PS and ± dL/dt; and prolonged
TPS and TR90 in whole hearts and isolated cardiomyo-
cytes in diabetic mice. These findings are similar to our
previous findings [17,28,29]. Several mechanisms may be
postulated for diabetes-related abnormalities such as
impaired intracellular Ca2+ homeostasis and oxidative
stress [28,29]. In our study, the impaired intracellular
Ca2+ handling (reduced intracellular Ca2+ clearance and
intracellular Ca2+ rise (ΔFFI)) may likely underscore the
prolonged duration of contraction and relaxation and the
reduced PS, maximal velocity of shortening and relength-
ening and fractional shortening observed in STZ-induced
diabetic mouse hearts. The fact that the ALDH2 transgene
reconciled STZ-induced intracellular Ca2+ mishandling
favors a possible role of intracellular Ca2+ homeostasis in
diabetes-induced myocardial dysfunction and ALDH2-
offered protection, somewhat reminiscent of the beneficial
role of mitochondrial protection against diabetes or obe-
sity-induced myocardial dysfunction [31,32]. Our findings
Figure 8 Western blot analysis of the mitochondrial proteins UCP-2 and PGC1a as well as the Ca2+ regulatory proteins SERCA2a, Na
+-Ca2+ exchanger and phospholamban in myocardium from FVB and ALDH2 mice treated with or without streptozotocin. (A)
Representative gel blots of UCP-2, PGC1a, SERCA2a, Na+-Ca2+ exchanger, phospholamban and GAPDH (loading control) using specific antibodies;
(B) UCP-2; (C) PGC1a; (D) SERCA2a; (E) Na+-Ca2+ exchanger; (F) phospholamban. All proteins were normalized to the loading control GAPDH.
Mean ± SEM, n = 5 to 6 mice per group. *P < 0.05 versus FVB group; #P < 0.05 versus FVB-STZ group.
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revealed a loss of mitochondrial membrane potential and
overt apoptosis (demonstrated by caspase-3 and TUNEL)
along with downregulated levels of PGC1a and UCP-2 in
STZ-induced diabetic hearts, suggesting a corroborative
role of mitochondrial dysfunction and apoptosis in dia-
betic cardiomyopathy, as reported previously [31].
In addition, our observations that the ALDH2 trans-
gene restored downregulated expression of SERCA2a and
Na+-Ca2+ exchanger as well as upregulated phospholam-
ban in diabetes also support a role of intracellular Ca2+
homeostasis in diabetes-induced cardiac contractile dys-
function and ALDH2-offered protection.
Perhaps our most significant finding is that ALDH2
overexpression reconciled diabetes-induced cardiac
remodeling (represented by cardiomyocyte cross-sec-
tional area, changes in LV wall thickness, ESD and
EDD) and contractile dysfunction in association with
preserved myocyte survival and mitochondrial integrity.
These beneficial effects of ALDH2 in cardiac geometry
and function, cell survival and mitochondrial integrity
were seen despite the persistent hyperglycemic and
hyperlipidemic environments in STZ-induced experi-
mental diabetes, thus excluding a possible secondary
effect for ALDH2-induced protection against diabetic
cardiomyopathy. This is further supported by the fact
that ALDH2 failed to alter global metabolism (RER and
physical activity) in diabetes. In our study, STZ failed to
elicit any hypertrophic effect as evidenced by absolute
heart weight and LV mass, although it enhanced cardio-
myocyte size and heart-to-body weight ratio, and nor-
malized LV mass. These effects were likely due to an
STZ-induced loss in body weight. Interestingly, ALDH2
overexpression attenuated diabetes-induced changes in
cardiomyocyte, heart and LV sizes, possibly due to the
Figure 9 Phosphorylation of Akt, GSK3b, mTOR and Foxo3a in myocardium from FVB and ALDH2 mice treated with or without
streptozotocin. (A) pAkt-to-Akt ratio; (B) pGSK3b-to-GSK3b ratio; (C) pmTOR-to-mTOR ratio; (D) pFoxo3a-to-Foxo3a ratio. Insets: representative
gel blots of pan and phosphorylated Akt, GSK3b, mTOR and Foxo3a (GAPDH as loading control) using specific antibodies. Mean ± SEM, n = 6 to
7 mice per group. *P < 0.05 versus FVB group; #P < 0.05 versus FVB-STZ group.
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antagonism of ALDH2 against diabetes-induced cardiac
apoptosis and mitochondrial damage. Both apoptosis
and mitochondrial damage are known to regulate car-
diac remodeling in diabetes and obesity [31,33]. Our
observation of preserved levels of the mitochondrial pro-
teins PGC1a and UCP-2 as well as of aconitase activity
and mitochondrial membrane potential in ALDH2 mice
after STZ treatment strongly supported a role of mito-
chondrial function in ALDH2-offered cardioprotection.
The therapeutic role of the mitochondrial protein
ALDH2 in diabetes is consistent with the fact that the
protein level and enzymatic activity of ALDH2 are both
reduced in experimental diabetes [13] (also seen in our
study) while inactive ALDH2 promotes hyperglycemia
and enhances the risk of diabetes [14].
It is noteworthy that the reduction in the ALDH2
expression and activity is relatively minor although such
subtle loss of ALDH2 may be sufficient to trigger overt
changes in mitochondrial integrity and cell survival.
Although it is beyond the scope of our current study, the
main substrate for ALDH2 detoxification, aldehydes, serve
as the main source for oxidative stress and pathological
changes in disease condition. Even with a moderately
reduced ALDH2 level, sublethal levels of aldehydes may
accumulate and interact with functional signaling systems
to impose oxidative damage and associated gene altera-
tions in response to the stress challenge [34]. The notion
that ALDH2 protects against diabetic cardiomyopathy
through preservation of mitochondrial integrity was
further substantiated by our in vitro findings. Our results
revealed that the ALDH2 activator Alda-1 effectively res-
cued against high glucose-induced mitochondrial and
mechanical dysfunctions, and this effect was nullified by
the mitochondrial uncoupling compound FCCP. These
data convincingly support the permissive role of mito-
chondria in ALDH2-offered cardioprotection against
hyperglycemia-induced anomalies.
Data from our study showed dampened phosphoryla-
tion of the post-insulin receptor signaling Akt, GSK3b
and Foxo3a in STZ-treated diabetic hearts, in line with
mitochondrial injury in diabetes and observations from
our earlier studies [28,35]. These signaling molecules
play an essential role in the maintenance of cardiac survi-
val, structure and function. Akt, GSK3b and mTOR are
essential post-insulin receptor signaling molecules, which
may be compromised after mitochondrial injury and con-
tribute to apoptosis and cardiac dysfunction in pathologi-
cal conditions [10,14,36]. Our data revealed that diabetes
Figure 10 Total and phosphorylated PTEN in myocardium from FVB and ALDH2 mice treated with or without streptozotocin. (A)
Representative gel blots of pan and phosphorylated PTEN and GAPDH (used as loading control) using specific antibodies; (B) pan PTEN
expression; (C) pPTEN levels; (D) pPTEN-to-PTEN ratio. Mean ± SEM, n = 6 mice per group. *P < 0.05 versus FVB group; #P < 0.05 versus FVB-STZ
group.
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dampened phosphorylation of Akt and its downstream
signaling molecules Foxo3a and GSK3b (although not
mTOR), the effect of which was nullified by ALDH2
transgene. The decrease in the phosphorylation of
Foxo3a and GSK3b is expected to result from dampened
Akt phosphorylation. The reduced phosphorylation of
Foxo3a appears to coincide with overt mitochondrial
injury (as evidenced by mitochondrial membrane poten-
tial and levels of PGC1a, UCP-2 and aconitase) and
apoptosis (demonstrated by caspase-3 and TUNEL
staining) after STZ treatment, as reported previously by
our group using the same diabetic model [35]. GSK3b, a
serine/threonine kinase downstream of Akt that is inacti-
vated by oxidative stress through the phosphorylation of
Ser9, serves as a negative regulator of cardiac hypertro-
phy and mitochondrial function through mitochondrial
permeation pore opening [24,25,37]. Data from our study
revealed that ALDH2 abrogated the diabetes-induced
decrease in GSK3b phosphorylation, aconitase activity
and levels of PGC1a and UCP-2, favoring a possible role
Figure 11 Influence of the ALDH2 agonist Alda-1 on high glucose-induced responses of aconitase activity and cardiomyocyte
contractile properties. Cardiomyocytes from control FVB mice were exposed to high glucose (HG; 30 mM) in the absence or presence of Alda-
1 (20 μM), the mitochondrial uncoupler FCCP (1 μM) or the GSK3b inhibitor SB216763 (10 μM) for 12 hours prior to assessment of mitochondrial
and mechanical properties. (A) Aconitase activity; (B) peak shortening (PS; normalized to cell length); (C) maximal velocity of shortening (+ dL/
dt); (D) maximal velocity of relengthening (- dL/dt); (E) time-to PS (TPS); (F) time-to-90% relengthening (TR90). Mean ± SEM, n = 5 isolations
(panel A) or 72 to 73 cells per group (Panel B-F). *P < 0.05 versus control group; #P < 0.05 versus HG group.
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of GSK3b signaling and mitochondrial protection in
ALDH2-offered cardioprotection. This is supported by
the finding that GSK3b inhibition using SB216763 and
mitochondrial uncoupling using FCCP respectively
ablated high glucose and Alda-1-induced mitochondrial
and mechanical changes.
Mitochondrial injury is known to compromise insulin
signaling at both insulin receptor and post-receptor
levels [30]. A recent report from our group revealed
that protection of mitochondrial integrity using cardiac-
specific overexpression of insulin-like growth factor 1
effectively alleviates high fat diet intake-induced loss of
insulin sensitivity, oxidative stress and contractile dys-
function in the heart [38], supporting the pivotal role of
mitochondria in the maintenance of cardiac insulin sig-
naling. Nonetheless, our data also depicted elevated
phosphorylation of the Akt negative regulator PTEN in
experimental diabetes, the effect of which was mitigated
by ALDH2. This finding favors a possible role for PTEN
in ALDH2 overexpression-rescued Akt activation in
experimental diabetes. These observations suggest that
ALDH2 offers cardioprotection against experimental
diabetes, possibly through suppressed PTEN phosphory-
lation and subsequently preserved Akt-GSK3b phos-
phorylation, leading to protected mitochondrial integrity.
Conclusion
In summary, findings from our present study reveal a role
of ALDH2 in the protection against diabetic cardiomyo-
pathy, possibly via an Akt-GSK3b-mediated preservation
of cell survival and mitochondrial integrity. These data
indicate not only a role of ALDH2 in the prevalence of
diabetic cardiomyopathy but also some therapeutic pro-
mise for ALDH2 in the management of diabetic compli-
cations. As the important cardioprotective aspects of
ALDH2 begin to be unveiled, clinical implications of
ALDH2, in particular ALDH2 polymorphism, still remain
to be explored. Further studies should focus on a better
elucidation of the link between the ALDH2 gene and car-
diovascular risk in diabetic populations.
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